AUSTIN, Texas, Sept. 04, 2026 (GLOBE NEWSWIRE) -- Rein Therapeutics ("Rein") (NASDAQ: RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines in orphan pulmonary and fibrosis indications, today announced that it will present a late-breaking poster at the European Respiratory Society (ERS) 2026 Congress taking place September 5-9, 2026, in Barcelona, Spain. Poster Presentation Title: Inhaled LTI-03 for idiopathic pulmonary fibrosis: a randomized dose escalation s
AUSTIN, Texas, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Rein Therapeutics ("Rein") (NASDAQ: RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines in orphan pulmonary and fibrosis indications, today announced that Brian Windsor, President and Chief Executive Officer of Rein Therapeutics, will present at the following investor conferences in September. 2026 Cantor Global Healthcare Conference Date & Time: Friday, September 11, 2026, at 8:00 a.m. ETLocation: New York,
Rein Therapeutics advances LTI-03 in IPF. RENEW enrollment tops 25%, with interim data expected in the fourth quarter of 2026.
Tipranks Press Release.
This is the newest page. Registered accounts read further back.